Gastroparesis Market Report 2026
Global Outlook – By Treatment Modality (Medications, Dietary Modifications, Medical Devices, Other Therapies), By Gastroparesis Type (Idiopathic, Diabetic, Post- Surgical, Other Types), By Patient Demographics (Pediatric Gastroparesis, Adult Gastroparesis), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels), By End User (Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings) - Market Size, Trends, Strategies, and Forecast to 2030
Gastroparesis Market Overview
• Gastroparesis market size has reached to $7.15 billion in 2025 • Expected to grow to $9.29 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Gastroparesis Market Acceleration Amidst Diabetes Trends • Market Trend: Transformative Drugs For Gastroparesis Management • North America was the largest region in 2025.What Is Covered Under Gastroparesis Market?
Gastroparesis is a medical condition characterized by the impairment or weakening of the stomach muscles, resulting in delayed emptying of stomach contents into the small intestine. Gastroparesis is treated by medications to stimulate stomach emptying and manage underlying conditions, and surgical interventions. The main treatment modalities of gastroparesis are medications, dietary modifications, medical devices, and others. Medications are substances that work by interacting with the body's biological processes to produce a desired effect. Medications such as prokinetic drugs, antiemetics, botulinum toxin injections, antidepressants, and others are used to diagnose, treat, cure, or prevent gastroparesis. These are used for the treatment of idiopathic, diabetic, post-surgical, and others in pediatric and adult patients. These are distributed by retail pharmacies, hospital pharmacies, and others, which are used by hospitals and clinics, ambulatory surgical centers, and home care settings.
What Is The Gastroparesis Market Size and Share 2026?
The gastroparesis market size has grown strongly in recent years. It will grow from $7.15 billion in 2025 to $7.52 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to diabetes-related gastric disorders, use of antiemetic medications, hospital-based gi care, dietary management approaches, availability of diagnostic imaging.What Is The Gastroparesis Market Growth Forecast?
The gastroparesis market size is expected to see strong growth in the next few years. It will grow to $9.29 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to innovation in implantable stimulation devices, growth in outpatient treatment models, rising diabetic population, demand for symptom-focused therapies, improved clinical awareness. Major trends in the forecast period include increased use of prokinetic medications, growing adoption of gastric electrical stimulation devices, rising focus on dietary and lifestyle management, expansion of minimally invasive surgical options, improved diagnosis of diabetic gastroparesis.
Global Gastroparesis Market Segmentation
1) By Treatment Modality: Medications, Dietary Modifications, Medical Devices, Other Therapies 2) By Gastroparesis Type: Idiopathic, Diabetic, Post- Surgical, Other Types 3) By Patient Demographics: Pediatric Gastroparesis, Adult Gastroparesis 4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels 5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings Subsegments: 1) By Medications: Prokinetic Agents, Antiemetic Medications, Pain Management Medications 2) By Dietary Modifications: Low-Fiber Diets, Small, Frequent Meals, Pureed Or Liquid Diets 3) By Medical Devices: Gastric Electrical Stimulation Devices, Enteral Feeding Tubes 4) By Other Therapies: Acupuncture, Behavioral Therapies, Nutritional SupplementsWhat Is The Driver Of The Gastroparesis Market?
The rapid surge in the prevalence of diabetes is expected to propel the growth of the gastroparesis market going forward. Diabetes is a chronic medical condition characterized by elevated levels of blood glucose resulting from the body's inability to produce enough insulin or effectively use the insulin it produces. The prevalence of diabetes significantly increases the likelihood of developing gastroparesis, as diabetes plays a pivotal role in expanding the population at risk for this condition. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based advocacy organization, reported that globally, nearly one in nine adults (589 million) are now living with diabetes. Of these, an estimated 252 million are not yet aware they have the condition, placing them at higher risk of serious complications and early death. Therefore, a rapid surge in the prevalence of diabetes is driving the gastroparesis industry.Key Players In The Global Gastroparesis Market
Major companies operating in the gastroparesis market are Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical Co. ltd, ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., RedHill Biopharma Ltd., CinRx Pharma LLC, Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., Neurogastrx Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Gastroparesis Market Trends and Insights
Major companies operating in gastroparesis market are developing drugs to increase their profitability in the market. Drugs used in the treatment of gastroparesis serve various purposes to address the symptoms associated with delayed stomach emptying. For instance, in December 2023, Vanda Pharmaceuticals Inc., a US-based, Biopharmaceutical Company, has reported that the U.S. FDA has accepted the New Drug Application for Tradipitant, a promising development in its potential approval for treating gastroparesis. The FDA has scheduled the decision date for Tradipitant under the Prescription Drug User Fee Act (PDUFA) on September 18, 2024. If successful, Tradipitant would mark the first FDA-approved novel drug for gastroparesis in over 40 years, representing a significant milestone in more than three decades for a drug to undergo FDA review specifically for gastroparesis.What Are Latest Mergers And Acquisitions In The Gastroparesis Market?
In May 2025, Dr. Falk Pharma, a Germany-based specialty pharmaceutical company focused on gastroenterology, partnered with Renexxion, to advance the development and commercialization of innovative gastrointestinal therapies. With this partnership, Dr. Falk Pharma and Renexxion aim to advance the clinical development and global commercialization of naronapride, a precision therapy for gastroparesis, combining regulatory expertise with novel prokinetic technology. Renexxion is a U.S.-based clinical-stage biotech focused on developing naronapride, a selective 5-HT4 agonist designed to improve gastric motility in patients with gastroparesis.
Regional Outlook
North America was the largest region in the gastroparesis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Gastroparesis Market?
The gastroparesis market consists of sales of metoclopramide, domperidone, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Gastroparesis Market Report 2026?
The gastroparesis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Gastroparesis Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $7.52 billion |
| Revenue Forecast In 2030 | $9.29 billion |
| Growth Rate | CAGR of 5.5% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Treatment Modality, Gastroparesis Type, Patient Demographics, Distribution Channel, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical Co. ltd, ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., RedHill Biopharma Ltd., CinRx Pharma LLC, Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., Neurogastrx Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |